ISSCR: grave omission of age limit for embryo research
By Josephine Johnston, Françoise Baylis, & Henry T. Greely,
Nature
| 06. 22. 2021
We are researchers with differing views on the ethics of stem-cell and embryo research who nonetheless share deep concerns about the latest guidelines from the International Society for Stem Cell Research (ISSCR; see R. Lovell-Badge Nature 593, 479; 2021).
The 2016 ISSCR guidelines ruled out experiments on human embryos beyond 14 days, citing broad international consensus that these lacked “a compelling scientific rationale, raise substantial ethical concerns, and/or are illegal in many jurisdictions” (see go.nature.com/3cqc4bw). The latest guidelines drop this prohibition (see go.nature.com/3gfkkw8) and do not propose any alternative.
At some point, the developing human embryo reaches a stage at which it should not be used for research. There is disagreement about when that happens, but scientists need to acknowledge that it does, and reassure the public that they accept limits. The latest guidelines do not prohibit the development or research use of ex vivo embryos at any stage.
Defining and defending a new limit, and possible constraints within it, will be hard. This was the case for the 14-day cut-off, selected some 40 years...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...